Welcome to Hu Said, a cardiology #MedEd podcast. Every episode cuts straight to the core of the topic, delivering the high-yield information you need to know for your exams. In this 2nd season of the podcast, new topics have been added, with >100 total topics. Whenever possible, evidence-based statements from the latest ACC/AHA/HRS/HFSA/SCAI guidelines are interwoven. Whether you are a resident, fellow, or re-certifying cardiologist, subscribe for precise, curated pearls. Ensure you get maximum knowledge in minimal time, because your time is valuable.
X: @ruey_hu
Materials: rueyhu.com/MedEd
2026 ACC Expert Consensus Decision Pathway on Heart Failure with Preserved Ejection Fraction
In what settings should you use the H₂FPEF, HFA-PEFF, and HFpEF-ABA scores in the diagnosis of HFpEF? What are HFpEF mimics? What is the difference between OMT and GDMT? Why is finerenone now preferred over spironolactone as the mineralocorticoid antagonist of choice in HFpEF? In which HFpEF patients should semaglutide or tirzepatide be prescribed? Why should ACE inhibitors be avoided in HFpEF, and which RAAS agents are actually supported by evidence? In which specific subgroups of HFpEF patients should sacubitril/valsartan be considered? Should HFpEF patients be given beta blockade? Which diabetes medications should be avoided in HFpEF patients, and which should replace them? How does the cardiovascular-kidney-metabolic framework help prioritize therapies with overlapping benefits across heart failure, diabetes, CKD, and obesity? Watch for answers to these key questions and more in this deep dive of the 2026 ACC Expert Consensus Decision Pathway on the Management of Heart Failure with Preserved Ejection Fraction.
Watch on YouTube: https://youtu.be/HazAsFCjiAI
Difficulty Level: Medium
You are listening to Hu Said: Guideline Lifeline
Please subscribe, rate, and support the channel! Ads help keep materials free for everyone.
More MedEd resources available at www.rueyhu.com (https://www.rueyhu.com)
Updates at Twitter/X: @Ruey_Hu (https://twitter.com/ruey_hu)
30 Jul 2026
2026 AHA/ACC/ESC/WHF Second Universal Definition of Heart Failure
Why did the 2026 universal definition abandon specific numerical cutoffs for HFrEF and HFpEF? What are the three positive trajectories that can emerge from symptomatic HF? How do impHF (heart failure with improvement), remHF (heart failure with remission), and recHF (heart failure with recovery) differ from one another? What is the distinction between worsening HF and decompensated HF? What are the categories in the new Universal Classification of HF by Cause? How does the cause of HF differ between geographic regions? Watch for answers to these key questions and more in this deep dive of the 2026 AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure.
Watch on YouTube: https://youtu.be/MR20wFklefg
Difficulty Level: Easy
You are listening to Hu Said: Guideline Lifeline
Please subscribe, rate, and support the channel! Ads help keep materials free for everyone.
More MedEd resources available at www.rueyhu.com (https://www.rueyhu.com)
Updates at Twitter/X: @Ruey_Hu (https://twitter.com/ruey_hu)
14 Mar 2026
2026 ACC/AHA Dyslipidemia Guideline
When should apoB be measured? In whom should lipoprotein(a) be measured? Should LDL-C be calculated by the Friedewald, Martin-Hopkins, or Sampson-NIH equations? How do the PREVENT-ASCVD equations differ from the Pooled Cohort Equations? How long is a coronary artery calcium (CAC) score of 0 "good for"? How should CAC scoring be used to guide statin initiation and intensity? What are the new LDL-C, non-HDL-C, and apoB targets for secondary prevention? What counts as "very high-risk" ASCVD, and how does treatment differ? In which patients should bempedoic acid, inclisiran, or olezarsen be added? Watch for answers to these key questions and more in this "deep dive" of the 2026 ACC/AHA Guideline on the Management of Dyslipidemia.Watch on YouTube: https://youtu.be/yHXL_dH8zCo
Difficulty Level: Easy
You are listening to Hu Said: Guideline Lifeline
Please subscribe, rate, and support the channel! Ads help keep materials free for everyone.
More MedEd resources available at www.rueyhu.com (https://www.rueyhu.com)
Updates at Twitter/X: @Ruey_Hu (https://twitter.com/ruey_hu)
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
Apple Podcasts (US)
4.5 / 5
17 ratings
Spotify
5.0 / 5
41 ratings
Contact Hu Said: Cardiology Board Review Series
Guest appearances
Books guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
